Drug Interactions between Niaspan and Pancrecarb MS-16
This report displays the potential drug interactions for the following 2 drugs:
- Niaspan (niacin)
- Pancrecarb MS-16 (pancrelipase)
Interactions between your drugs
No interactions were found between Niaspan and Pancrecarb MS-16. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Niaspan
A total of 104 drugs are known to interact with Niaspan.
- Niaspan is in the following drug classes: miscellaneous antihyperlipidemic agents, vitamins.
- Niaspan is used to treat the following conditions:
Pancrecarb MS-16
A total of 26 drugs are known to interact with Pancrecarb MS-16.
- Pancrecarb ms-16 is in the drug class digestive enzymes.
- Pancrecarb ms-16 is used to treat the following conditions:
Drug and food interactions
niacin food
Applies to: Niaspan (niacin)
GENERALLY AVOID: Ethanol can exacerbate the cutaneous flushing that is a common side effect of niacin. At least one case of delirium and lactic acidosis has been reported with coadministration of these drugs, although data are limited.
MANAGEMENT: Coadministration should probably be discouraged, particularly since chronic consumption of large amounts of alcohol is associated with hyperlipidemia.
References
- Schwab RA, Bachhuber BH "Delirium and lactic acidosis caused by ethanol and niacin coingestion." Am J Emerg Med 9 (1991): 363-5
pancrelipase food
Applies to: Pancrecarb MS-16 (pancrelipase)
MONITOR: Exogenous pancreatic enzymes may interfere with the gastrointestinal absorption of folic acid and iron. The exact mechanism of interaction is unknown. In one study, investigators compared oral iron absorption over a 3-hour period in the presence and absence of exogenous pancreatic enzymes in 13 stable young adults with cystic fibrosis and 9 age-matched controls. There was no difference between patients and controls in iron absorption in the absence of exogenous pancreatic enzymes. However, significant impairment of iron absorption was observed in both groups after administration of pancrelipase one hour prior to iron administration. In the patient group, one hour after iron administration, there was a 188% increase in serum iron level above baseline in the absence of pancrelipase but only a 62% increase in the presence of pancrelipase. In the controls, percentage increases as well as peak serum iron levels were significantly higher in the absence of pancrelipase during all 3 hours after iron administration. Clinically, at least one-third of cystic fibrosis patients reportedly have iron deficiency. In the study, mean serum iron concentration was significantly lower in patients than in controls (11.9 versus 18.9 micromoles/L), and 5 of the patients but none of the controls had a serum iron concentration lower than 9 micromoles/L at baseline, presumably due to long-term treatment with pancreatic enzyme supplements.
MANAGEMENT: Patients receiving therapeutic iron or folate therapy should be monitored for potentially reduced hematologic response if pancreatic enzymes are administered concomitantly. Separating the times of administration may be helpful.
References
- "Product Information. Cotazym (pancrelipase)." Organon PROD (2001):
- Zempsky WT, Rosenstein BJ, Carroll JA, Oski FA "Effect of pancreatic enzyme supplements on iron absorption." Am J Dis Child 143 (1989): 969-72
- Dietze F, Bruschke G "Inhibition of iron absorption by pancreatic extracts." Lancet 1 (1970): 424
- "Product Information. L-Methylfolate Calcium (l-methylfolate)." Virtus Pharmaceuticals LLC (2018):
niacin food
Applies to: Niaspan (niacin)
A single case has been reported in which cutaneous flushing and tremors were noted in a woman who was taking niacin while wearing a nicotine patch. The mechanism is suspected to be synergistic cutaneous vasodilatory effects. The clinical significance of this possible interaction is not known.
References
- Rockwell KA Jr "Potential interaction between niacin and transdermal nicotine." Ann Pharmacother 27 (1993): 1283-8
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.